A Need for Reorganization of the Food and Drug Administration

被引:0
作者
Edlich, Richard F. [1 ]
Mason, Shelley S. [2 ]
Reddig, Jill S. [2 ]
Gubler, K. Dean [3 ]
Long, William B., III
机构
[1] Univ Virginia Hlth Syst, Charlottesville, VA USA
[2] Multiple Sclerosis Res Fund, Brush Prairie, WA USA
[3] Legacy Emanuel Hosp, Legacy Verified Level Shock Trauma Ctr Pediat & A, Trauma Specialists LLP, Portland, OR USA
关键词
Food and Drug Administration; Center for Devices and Radiological Health; citizen's petition; Grassley-Dodd bill; Government Accountability Office; Food and Drug Administration Safety Act of 2007;
D O I
10.1615/JEnvironPatholToxicolOncol.v29.i2.10
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
The associate director for science and medicine in the Office of Drug Safety at the Food and Drug Administration (FDA), Dr. David Graham, reported that the FDA was incapable of protecting Americans from unsafe drugs. In testimony to the Senate Finance Committee, he stated that the FDA has let the American people down and betrayed public trust. Drastic changes and measures within the FDA must be made to ensure the safety of American consumers of drugs, products, and medical devices. Efforts such as the introduction of the Grassley-Dodd Bill, allowing the FDA to order immediate drug recall or increased risk warnings, followed by the FDA Safety Act of 2007, are still not enough to ensure the safety and efficacy of drugs, biological products, and medical devices that the American public use every day. In this report, we describe past and present efforts by congressional leaders, FDA representatives, and American citizens to effect changes within the FDA in order to protect America from unsafe drugs and medical devices. We describe our own struggles in passing a citizen's petition to ban cornstarch in medical gloves, and the lack of response and responsibility that the FDA has displayed.
引用
收藏
页码:81 / 84
页数:4
相关论文
共 50 条
[32]   The New Food and Drug Administration Approved Drugs in 2014: a 2015 Report Analysis [J].
Santos, Wilson C. ;
da Silva, Fernando C. ;
Pinto, Angelo C. ;
Ferreira, Vitor F. .
REVISTA VIRTUAL DE QUIMICA, 2015, 7 (04) :1535-1551
[33]   Responding to the Clopidogrel Warning by the US Food and Drug Administration Real Life Is Complicated [J].
Roden, Dan M. ;
Shuldiner, Alan R. .
CIRCULATION, 2010, 122 (05) :445-448
[34]   Opportunities for Consumer Research from the Food and Drug Administration's Center for Tobacco Products [J].
Andrews, J. Craig ;
Choiniere, Conrad J. ;
Portnoy, David B. .
JOURNAL OF PUBLIC POLICY & MARKETING, 2015, 34 (01) :119-130
[35]   Food and Drug Administration warning on anesthesia and brain development: implications for obstetric and fetal surgery [J].
Olutoye, Olutoyin A. ;
Baker, Byron Wycke ;
Belfort, Michael A. ;
Olutoye, Oluyinka O. .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2018, 218 (01) :98-102
[36]   Clinical utility of the Food and Drug Administration Electrocardiogram Warehouse: a paradigm for the critical pathway initiative [J].
Cabell, CH ;
Noto, TC ;
Krucoff, MW .
JOURNAL OF ELECTROCARDIOLOGY, 2005, 38 (04) :175-179
[37]   A new analytic tool for assessing the impact of the US Food and Drug Administration regulatory actions [J].
Lu, Christine Y. ;
Hou, Laura ;
Kolonoski, Joy ;
Petrone, Andrew B. ;
Zhang, Fang ;
Corey, Catherine ;
Huang, Ting-Ying ;
Bradley, Marie C. .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 (03) :298-311
[38]   Review of novel and supplemental approvals of the targeted cancer drugs by the Food and Drug Administration in 2021 [J].
Kandemir, Esin Aysel .
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2023, 29 (01) :191-207
[39]   When are medical apps medical? Off-label use and the Food and Drug Administration [J].
Krieger, William H. .
DIGITAL HEALTH, 2016, 2
[40]   Working with the US Food and Drug Administration to obtain approval of products under the Animal Rule [J].
Park, Glen D. ;
Mitchel, Jules T. .
COUNTERMEASURES AGAINST CHEMICAL THREATS, 2016, 1374 :10-16